PSMA PET/CT scan for liver cancer (HCC)
Part of Cancer, Digestive system clinical trials.
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of hepatocellular carcinoma (HCC, a type of liver cancer) that is either confirmed by biopsy or seen on scans (CT/MRI), or you need a new scan to check if the cancer has come back or spread.
- You must have at least one tumor that can be seen on a CT or MRI scan.
- You must be well enough to do daily activities (like walking and dressing) – this is called ECOG 0-2.
- Your liver function must be good (Child-Pugh A, determined by blood tests).
- You must not have serious heart disease, uncontrolled illnesses, or have had certain treatments (like radioembolization) in the last 3 months.
- You must not be pregnant or breastfeeding, and must agree to use two forms of contraception for several months after the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This study uses a special PET/MRI scan with a tracer called PSMA-11 to look at how liver cirrhosis affects the liver. It may help doctors better understand and monitor the disease.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.